Pharmacists' Perceptions on Real-time Prescription Monitoring (RTPM) Systems - a Cross-sectional Survey

Overview

Journal Explor Res Clin Soc Pharm

Date 2022 Apr 28

PMID 35478517

Authors

Ziyue Zhang

Lin Guo

Ran Si

Leanne Chalmers

Patricia Filippin

Jane Carpenter

Petra Czarniak

Affiliations

Soon will be listed here.

Abstract

Background: Real-time prescription monitoring (RTPM) systems are an effective tool to help health practitioners monitor opioid use and reduce opioid-related harm but little has been reported about the support required by pharmacists to engage with them effectively in practice.

Objective: To evaluate the current understanding and perceptions of Western Australian pharmacists regarding RTPM systems and opioid-related harm, and investigate their self-reported training and support requirements prior to RTPM system implementation.

Methods: This cross-sectional, prospective study involved an online Qualtrics survey distributed to Western Australian community or hospital pharmacists involved in dispensing and patient-centred roles via local professional pharmacy newsletters and social media. Data collection included demographic information, responses to authentic case scenarios and Likert-scale questions regarding perceptions and training requirements of a RTPM system, pain management and opioid-related harm. Descriptive analysis was utilised.

Result: Sixty-two pharmacists responded to the questionnaire. Most (58/61; 95.1%) had a positive attitude towards RTPM systems, but only 33/61 (54.1%) reported being prepared for its implementation. Perceived barriers to successful implementation included lack of remuneration (46/60; 76.6%), conflict with prescribers (40/60; 66.7%), increased workload (37/60; 61.7%), staff safety concerns (34/60; 56.7%) and lack of knowledge regarding RTPM systems (32/60; 53.3%). Even though most participants were satisfied with training previously received, over 90% reported requiring further training and education, especially regarding RTPM systems (51/57; 96.2%) and opioid-related harm (56/57; 98.2%).

Conclusion: Among a small sample of participants, there was a strong positivity regarding the value of RTPM systems and a high degree of receptiveness to further training in preparation for RTPM implementation.

Citing Articles

What influences Australian pharmacists' decisions to supply opioids? Results from a survey and randomised controlled factorial experiment.

Picco L, Xia T, Laing R, Grist E, Dostal J, Nielsen S Drug Alcohol Rev. 2025; 44(3):783-792.

PMID: 39916423 PMC: 11886474. DOI: 10.1111/dar.14009.

References

Gosdin M, Pugliese J, Wintemute G, Henry S . Philosophical Barriers to Using Prescription Drug Monitoring Programs: Results from a Statewide Survey. Pain Med. 2019; 20(8):1636-1637. PMC: 7963206. DOI: 10.1093/pm/pnz033. View

Alley L, Novak K, Havlin T, Irwin A, Carson J, Johnston K . Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists. Res Social Adm Pharm. 2020; 16(10):1422-1430. DOI: 10.1016/j.sapharm.2019.12.023. View

Sim T, Wright B, Hattingh L, Parsons R, Sunderland B, Czarniak P . A cross-sectional survey of enhanced and extended professional services in community pharmacies: A pharmacy perspective. Res Social Adm Pharm. 2019; 16(4):511-521. DOI: 10.1016/j.sapharm.2019.07.001. View

Gibbins A, Wood P, Spark M . Managing inappropriate use of non-prescription combination analgesics containing codeine: A modified Delphi study. Res Social Adm Pharm. 2016; 13(2):369-377. DOI: 10.1016/j.sapharm.2016.02.015. View

Chisholm-Burns M, Spivey C, Sherwin E, Wheeler J, Hohmeier K . The opioid crisis: Origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm. 2019; 76(7):424-435. DOI: 10.1093/ajhp/zxy089. View

Hamer A, Spark M, Wood P, Roberts E . The upscheduling of combination analgesics containing codeine: the impact on the practice of pharmacists. Res Social Adm Pharm. 2013; 10(4):669-78. DOI: 10.1016/j.sapharm.2013.08.004. View

Haines S, Savic M, Picco L, Nielsen S, Carter A . Unintended consequences of using real time prescription monitoring systems. Med J Aust. 2020; 213(3):142-142.e1. DOI: 10.5694/mja2.50616. View

Hagemeier N, Gray J, Pack R . Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013; 48(9):761-8. DOI: 10.3109/10826084.2013.787101. View

Freeman P, Curran G, Drummond K, Martin B, Teeter B, Bradley K . Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Res Social Adm Pharm. 2018; 15(6):754-760. PMC: 6417986. DOI: 10.1016/j.sapharm.2018.09.007. View

10.

Hoppe D, Ristevski E, Khalil H . The attitudes and practice strategies of community pharmacists towards drug misuse management: A scoping review. J Clin Pharm Ther. 2019; 45(3):430-452. DOI: 10.1111/jcpt.13100. View

11.

Dube P, Vachon J, Sirois C, Roy E . Opioid prescribing and dispensing: Experiences and perspectives from a survey of community pharmacists practising in the province of Quebec. Can Pharm J (Ott). 2018; 151(6):408-418. PMC: 6293395. DOI: 10.1177/1715163518805509. View

12.

Johnston K, Alley L, Novak K, Haverly S, Irwin A, Hartung D . Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. J Am Pharm Assoc (2003). 2018; 58(5):568-576. DOI: 10.1016/j.japh.2018.06.003. View

13.

Langford A, Gnjidic D, Lin C, Bero L, Penm J, Blyth F . Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis. BMJ Qual Saf. 2020; 30(2):133-140. DOI: 10.1136/bmjqs-2020-010881. View

14.

Gregory T, Gregory L . The Role of Pharmacists in Safe Opioid Dispensing. J Pharm Pract. 2019; 33(6):856-862. DOI: 10.1177/0897190019852803. View

15.

Fischer B, Jones W, Vojtila L, Kurdyak P . Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. Pain Physician. 2018; 21(3):219-228. View

16.

Leong C, Alessi-Severini S, Sareen J, Enns M, Bolton J . Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada. Subst Use Misuse. 2016; 51(13):1724-30. DOI: 10.1080/10826084.2016.1197261. View

17.

Fendrich M, Bryan J, Hooyer K . Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances. Subst Use Misuse. 2018; 53(8):1324-1330. DOI: 10.1080/10826084.2017.1408650. View

18.

Irwin A, Novak K, Alley L, Havlin T, OKane N, Johnston K . Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge. J Am Pharm Assoc (2003). 2020; 60(3):450-455.e3. DOI: 10.1016/j.japh.2019.11.030. View

19.

Cochran G, Field C, Lawson K . Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice. J Pharm Pract. 2014; 28(4):404-12. DOI: 10.1177/0897190014522064. View

20.

Nielsen S, Picco L, Kowalski M, Sanfilippo P, Wood P, Larney S . Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. Res Social Adm Pharm. 2020; 16(12):1694-1701. DOI: 10.1016/j.sapharm.2020.02.009. View